1
|
Potestio L, Genco L, Villani A, Marasca C, Fabbrocini G, Fornaro L, Ruggiero A, Martora F. Reply to 'Cutaneous adverse effects of the available COVID-19 vaccines in India: A questionnaire-based study'. by Bawane J et al. J Eur Acad Dermatol Venereol 2022; 36:e863-e864. [PMID: 35723893 PMCID: PMC9349951 DOI: 10.1111/jdv.18341] [Citation(s) in RCA: 26] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- L Potestio
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131, Napoli, Italy
| | - L Genco
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131, Napoli, Italy
| | - A Villani
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131, Napoli, Italy
| | - C Marasca
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131, Napoli, Italy
| | - G Fabbrocini
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131, Napoli, Italy
| | - L Fornaro
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131, Napoli, Italy
| | - A Ruggiero
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131, Napoli, Italy
| | - F Martora
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Via Pansini 5, 80131, Napoli, Italy
| |
Collapse
|
2
|
Rimini M, Fabregat C, Burgio V, Lonardi S, Niger M, Scartozzi M, Rapposelli I, Aprile G, Ratti F, Pedica F, Macarulla T, Fassan M, Pretta A, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei Gardini A. PD-5 IDH1 in intrahepatic cholangiocarcinoma: A comparative genomic analysis and clinical impact. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.083] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
3
|
Rimini M, Macarulla T, Burgio V, Lonardi S, Niger M, Scartozzi M, Rapposelli I, Aprile G, Ratti F, Pedica F, Nappo F, Fabregat C, Fassan M, Frassineti G, Simionato F, De Cobelli F, Aldrighetti L, Fornaro L, Cascinu S, Casadei Gardini A. SO-3 Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.402] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Bueno C, Alves FL, Pinheiro LM, Perez L, Agostini VO, Fernandes EHL, Möller OO, Weschenfelder J, Pinho GLL, Wallner-Kersanach M, Moura RR, Durán JM, Etchevers I, Costa LDF, Werlang CC, Bortolin E, Machado E, Figueira RCL, Ferreira PAL, Andrade C, Fornaro L, García-Rodríguez F. The effect of agricultural intensification and water-locking on the world's largest coastal lagoonal system. Sci Total Environ 2021; 801:149664. [PMID: 34418619 DOI: 10.1016/j.scitotenv.2021.149664] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/19/2021] [Revised: 07/20/2021] [Accepted: 08/10/2021] [Indexed: 06/13/2023]
Abstract
The palaeolimnological conditions of Mirim Lagoon, a large coastal shallow lagoon under the influence of historical human impacts related to the development of the primary sector of the economy were reconstructed. The first significant human impact consisted of locking the estuarine system to induce the transition from brackish to freshwater conditions. During this transition, the sedimentation rate consistently increased from pre-disturbance values of 0.25 cm yr-1 to >1 cm yr-1. A concomitant increase in nitrogen and carbon values was recorded indicating a related eutrophication process. The highest nutrient levels were achieved during the 1990s after the incorporation of cutting-edge technologies for agricultural production such as high-yielding varieties of rice resistant to climate variability and pests, and the use of inorganic fertilisers, pesticides and water supply controlled by irrigation. After 2011, the soybean production boosted and the area cultivated with this oilseed equalled the area of rice paddies, i.e., 2 × 105 ha. A sharp decrease in δ13C from -19 to -24‰ and in δ15N from 6 to 2‰ were observed in the sedimentary record, indicating a major shift in the composition of the organic matter after the agricultural intensification. Trace elements Cr, Cu, Ni and Zn showed a high positive correlation with Al and Fe, and enrichment factors near 1, indicating a natural and terrigenous source of these elements and also unpolluted conditions. However, the increase of As after 1990 and the positive correlation with Pb was associated with agricultural practices. All elemental ratios (K/Al, Ti/Al and V/Cr) showed constant pre-disturbance trends and a turning point ca. the 1990s. Microplastics were detected from the beginning of the 1990s and increased towards recent sediments, thus corroborating an anthropogenically impacted scenario. Therefore, the development of the primary sector of the economy exerted clear impacts on the environmental quality of the system.
Collapse
Affiliation(s)
- C Bueno
- Oceanografía y Ecología Marina, Instituto de Ecología y Ciencias Ambientales, Facultad de Ciencias, Universidad de la República, Iguá 4225, Montevideo, Uruguay.
| | - F L Alves
- Instituto de Oceanografia, Universidade Federal do Rio Grande (FURG), Rio Grande, Brazil
| | - L M Pinheiro
- Instituto de Oceanografia, Universidade Federal do Rio Grande (FURG), Rio Grande, Brazil
| | - L Perez
- Centro Universitario Regional del Este (CURE), Universidad de la República, Rocha, Uruguay
| | - V O Agostini
- Instituto de Oceanografia, Universidade Federal do Rio Grande (FURG), Rio Grande, Brazil
| | - E H L Fernandes
- Instituto de Oceanografia, Universidade Federal do Rio Grande (FURG), Rio Grande, Brazil
| | - O O Möller
- Instituto de Oceanografia, Universidade Federal do Rio Grande (FURG), Rio Grande, Brazil
| | - J Weschenfelder
- Centro de Estudos de Geologia Costeira e Oceânica, Instituto de Geociências, Universidade Federal do Rio Grande do Sul (UFRGS), Porto Alegre, Brazil
| | - G L L Pinho
- Instituto de Oceanografia, Universidade Federal do Rio Grande (FURG), Rio Grande, Brazil
| | - M Wallner-Kersanach
- Instituto de Oceanografia, Universidade Federal do Rio Grande (FURG), Rio Grande, Brazil
| | - R R Moura
- Instituto de Oceanografia, Universidade Federal do Rio Grande (FURG), Rio Grande, Brazil
| | - J M Durán
- Facultad de Administración y Ciencias Sociales, Universidad ORT, Uruguay
| | - I Etchevers
- Centro Universitario Regional del Este (CURE), Universidad de la República, Rocha, Uruguay
| | - L D F Costa
- Instituto de Oceanografia, Universidade Federal do Rio Grande (FURG), Rio Grande, Brazil
| | - C C Werlang
- Instituto de Oceanografia, Universidade Federal do Rio Grande (FURG), Rio Grande, Brazil
| | - E Bortolin
- Instituto de Oceanografia, Universidade Federal do Rio Grande (FURG), Rio Grande, Brazil
| | - E Machado
- Instituto de Oceanografia, Universidade Federal do Rio Grande (FURG), Rio Grande, Brazil
| | - R C L Figueira
- Laboratório de Química Inorgânica Marinha, Instituto Oceanográfico, Universidade de São Paulo, São Paulo, SP, Brazil
| | - P A L Ferreira
- Laboratório de Química Inorgânica Marinha, Instituto Oceanográfico, Universidade de São Paulo, São Paulo, SP, Brazil
| | - C Andrade
- Instituto de Oceanografia, Universidade Federal do Rio Grande (FURG), Rio Grande, Brazil
| | - L Fornaro
- Centro Universitario Regional del Este (CURE), Universidad de la República, Rocha, Uruguay
| | - F García-Rodríguez
- Instituto de Oceanografia, Universidade Federal do Rio Grande (FURG), Rio Grande, Brazil; Centro Universitario Regional del Este (CURE), Universidad de la República, Rocha, Uruguay
| |
Collapse
|
5
|
Tabernero J, Shitara K, Zaanan A, Doi T, Lorenzen S, Van Cutsem E, Fornaro L, Catenacci DVT, Fougeray R, Moreno SR, Azcue P, Arkenau HT, Alsina M, Ilson DH. Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study. ESMO Open 2021; 6:100200. [PMID: 34175675 PMCID: PMC8253956 DOI: 10.1016/j.esmoop.2021.100200] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Revised: 06/01/2021] [Accepted: 06/02/2021] [Indexed: 10/29/2022] Open
Abstract
BACKGROUND Metastatic gastric cancer and cancer of the esophagogastric junction (GC/EGJ) is an aggressive disease with poor prognosis. In the TAGS study, trifluridine/tipiracil (FTD/TPI) improved overall survival (OS) compared with placebo in heavily pre-treated patients. This unplanned, exploratory subgroup analysis of the TAGS study aimed to clarify outcomes when FTD/TPI was used as third-line (3L) treatment and fourth- or later-line (4L+) treatment. PATIENTS AND METHODS Patients were divided into a 3L group (126 and 64 in FTD/TPI and placebo arms, respectively) and 4L+ group (211 and 106 in FTD/TPI and placebo arms, respectively). Endpoints included OS, progression-free survival (PFS), time to Eastern Cooperative Oncology Group performance status (ECOG PS) deterioration to ≥2, and safety. RESULTS Baseline characteristics were generally well balanced between FTD/TPI and placebo for 3L and 4L+ treatment. Median OS (mOS) for FTD/TPI versus placebo was: 6.8 versus 3.2 months {hazard ratio (HR) [95% confidence interval (CI)] = 0.68 (0.47-0.97), P = 0.0318} in the 3L group; and 5.2 versus 3.7 months [0.73 (0.55-0.95), P = 0.0192] in the 4L+ group. Median PFS for FTD/TPI versus placebo was 3.1 versus 1.9 months [0.54 (0.38-0.77), P = 0.0004] in the 3L group; and 1.9 versus 1.8 months [0.57 (0.44-0.74), P < 0.0001] in the 4L+ group. Time to deterioration of ECOG PS to ≥2 for FTD/TPI versus placebo was 4.8 versus 2.0 months [HR (95% CI) = 0.60 (0.42-0.86), P = 0.0049] in the 3L group; and 4.0 versus 2.5 months [0.75 (0.57-0.98), P = 0.0329] in the 4L+ group. The safety of FTD/TPI was consistent in all subgroups. CONCLUSIONS This analysis confirms the efficacy and safety of FTD/TPI in patients with GC/EGJ in third and later lines with a survival benefit that seems slightly superior in 3L treatment. When FTD/TPI is taken in 3L as recommended in the international guidelines, physicians can expect to provide patients with an mOS of 6.8 months.
Collapse
Affiliation(s)
- J Tabernero
- Department of Medical Oncology, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), IOB-Quiron, UVic-UCC, Barcelona, Spain.
| | - K Shitara
- Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan
| | - A Zaanan
- Department of Gastrointestinal Oncology, European Georges Pompidou Hospital, AP-HP Centre, University of Paris, Paris, France
| | - T Doi
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Chiba, Japan
| | - S Lorenzen
- Third Department of Internal Medicine (Hematology/Medical Oncology), Klinikum Rechts der Isar, Technische Universitaet München, München, Germany
| | - E Van Cutsem
- Department of Gastroenterology and Digestive Oncology, University Hospital Gasthuisberg and University of Leuven, Leuven, Belgium
| | - L Fornaro
- Division of Oncology, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy
| | - D V T Catenacci
- Gastrointestinal Oncology Program, University of Chicago Medical Center, Chicago, USA
| | - R Fougeray
- Centre of EXcellence Methodology and Valorization of Data (CentEX MVD), Institut de Recherches Internationales Servier, Suresnes, France
| | - S R Moreno
- Global Medical and Patient Affairs, Les Laboratoires Servier SAS, Suresnes, France
| | - P Azcue
- Global Medical and Patient Affairs, Les Laboratoires Servier SAS, Suresnes, France
| | - H-T Arkenau
- Drug Development Unit, Sarah Cannon Research Institute UK Limited, London, UK
| | - M Alsina
- Department of Medical Oncology, Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona, Spain
| | - D H Ilson
- Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, New York, USA
| |
Collapse
|
6
|
Bañobre C, Diaz-Francés I, Scarabino F, Fornaro L, García-Tenorio R. 210Po levels and distribution in different environmental compartments from a coastal lagoon. The case of Briozzo lagoon, Uruguay. J Environ Radioact 2020; 222:106352. [PMID: 32892906 DOI: 10.1016/j.jenvrad.2020.106352] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/30/2019] [Revised: 06/05/2020] [Accepted: 07/05/2020] [Indexed: 06/11/2023]
Abstract
This paper presents the levels and distribution of 210Po in different compartments of a coastal lagoon on the east coast of Uruguay (South America). Activity concentrations of 210Po have been obtained in different matrices, such as water, superficial sediments, clams (Diplodon sp.), freshwaters snails (Pomacea sp.), zooplankton, and fishes (Jenynsia sp.), collected at different points of the lagoon and during several sampling campaigns. In addition, the organic matter content of the sediment was determined to study the variation of 210Po along the lagoon. The activity concentrations of 210Po in the water samples are in the range between 1.1 ± 0.2-3.5 ± 0.4 mBq/L while in the sediment samples vary between 17.1 ± 1.4 and 540 ± 12 Bq/kg, DW. In the case of biota, the ranges obtained were 182 ± 5-265 ± 6 Bq/kg, DW in clams and 134 ± 4-1245 ± 16 Bq/kg, DW in snail samples. A good correlation of 210Po with the organic fractions of the sediment was observed (r = 0.8798, p-value < 0.001), being obtained high values for the distribution coefficient Kd (104 -105). In the biota samples, a clear difference was observed in the 210Po concentration values in both species, mainly due to the different feeding habits of both aquatic organisms, as it is reflected in the associated concentration ratios (CR). In this paper, a good set of results of 210Po, Kd, and CR have been obtained in different matrices, enhancing the limited archives available for modelers concerning these parameters for 210Po and freshwater systems.
Collapse
Affiliation(s)
- C Bañobre
- Centro Universitario Regional del Este, Universidad de la República, Rocha, 27000, Uruguay.
| | - I Diaz-Francés
- Grupo Física Nuclear Aplicada, Universidad de Sevilla, Sevilla, 41012, Spain
| | - F Scarabino
- Centro Universitario Regional del Este, Universidad de la República, Rocha, 27000, Uruguay
| | - L Fornaro
- Centro Universitario Regional del Este, Universidad de la República, Rocha, 27000, Uruguay
| | - R García-Tenorio
- Grupo Física Nuclear Aplicada, Universidad de Sevilla, Sevilla, 41012, Spain; Centro Nacional de Aceleradores (Universidad de Sevilla-Junta de Andalucía-CSIC), Sevilla, 41092, Spain
| |
Collapse
|
7
|
Yoon H, Fuchs C, Özgüroğlu M, Bang Y, Bartolomeo MD, Mandala M, Ryu M, Fornaro L, Olesinski T, Caglevic C, Chung H, Muro K, Cutsem EV, Elme A, Thuss-Patience P, Chau I, Ohtsu A, Wang A, Bhagia P, Lin J, Shih C, Shitara K. O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.065] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
8
|
Pecora I, Vivaldi C, Rovesti G, Catanese S, Salani F, Gardini AC, Massa V, Bernardini L, Riggi M, Andrikou K, Rapposelli I, Formica V, Cesario S, Caccese M, Lencioni M, Vasile E, Falcone A, Fornaro L. P-188 Safety and efficacy of first-line gemcitabine plus nab-paclitaxel for elderly metastatic pancreatic cancer patients. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
9
|
Salani F, Pecora I, Vivaldi C, Massa V, Catanese S, Bernardini L, Caccese M, Cesario S, Vasile E, Lencioni M, Fornaro L, Falcone A, Masi G. P-219 Clear cell variant of hepatocellular carcinoma (HCC-CC): A single-center observational study of an uncommon subtype. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.04.301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
10
|
Casadei-Gardini A, Marisi G, Dadduzio V, Faloppi L, Ielasi L, Vivaldi C, Rizzato M, Fornaro L, Lonardi S, Gramantieri L, Pecora I, Silvestris N, Fornari F, Orsi G, Rovesti G, Santini D, Zagonel V, Cascinu S, Scartozzi M. Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.074] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Vivaldi C, Ugolini C, Orsi G, Formica V, Catanese S, Andrea C, Andrikou K, Doldo E, Pecora I, Campani D, Bonetti LR, Pasquini G, Salani F, Massa V, Niccoli C, Lencioni M, Vasile E, Gardini AC, Fornaro L, Fontanini G, Cascinu S, Falcone A. Characterization of mismatch repair deficiency in biliary tract cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
12
|
Casadei Gardini A, Marisi G, Dadduzio V, Ielasi L, Vivaldi C, Rizzato M, Fornaro L, Lonardi S, Gramantieri L, Pecora I, Foschi F, Silvestris N, Fornari F, Orsi G, Rovesti G, Santini D, Zagonel V, Cascinu S, Scartozzi M. Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz156.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
13
|
Catanese S, Aringhieri G, Cappelli C, Vivaldi C, Vitali S, Pecora I, Salani F, Pasquini G, Balducci F, Piercarlo R, Lencioni M, Vasile E, Massa V, Falcone A, Caramella D, Fornaro L. Baseline computed-tomography (CT)-evaluated sarcopenia predicts toxicity from first-line chemotherapy in metastatic gastric cancer (mGC) patients. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.298] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Fornaro L, Vivaldi C, Orlandi P, Musettini G, Pecora I, Gentile D, Catanese S, Lencioni M, Salani F, Pasquini G, Massa V, Di Desidero T, Falcone A, Vasile E, Bocci G. Longitudinal evaluation of angiogenesis-related circulating biomarkers during second-line treatment with paclitaxel and ramucirumab in advanced gastroesophageal cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz155.318] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
Franco P, Montagnani F, Arcadipane F, Casadei C, Andrikou K, Franco G, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Cascinu S, Ricardi U, Casadei Gardini A. Immune Inflammation Indicators Predict Outcome in Anal Cancer Patients Undergoing Concurrent Chemoradiation. Int J Radiat Oncol Biol Phys 2018. [DOI: 10.1016/j.ijrobp.2018.07.204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
16
|
Santini D, Brandi G, Aprile G, Russano M, Cereda S, Leone F, Lonardi S, Fornaro L, Scartozzi M, Silvestris N, Barni S, Pantano F, Vincenzi B, Palloni A, Frega G, Casagrande M, Ferrari L, Dadduzio V, Intini R, Filippi R, Vasile E, Vivaldi C, Faloppi L, Brunetti O, Reni M, Aglietta M, Tonini G. Bone metastases in biliary cancers: A multicenter retrospective survey. J Bone Oncol 2018; 12:33-37. [PMID: 30042924 PMCID: PMC6054714 DOI: 10.1016/j.jbo.2017.11.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2017] [Revised: 11/18/2017] [Accepted: 11/24/2017] [Indexed: 10/24/2022] Open
Abstract
•Natural history of biliary cancers metastatic to bone•The role of skeletal events in patients with biliary cancer•Biliary cancer and bone metastases: role of bisphosphonates.
Collapse
Affiliation(s)
- D Santini
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - G Brandi
- Department of Experimental, Diagnostic and Speciality Medicine, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
| | - G Aprile
- Department of Oncology, San Bortolo Hospital, ULSS8 Berica–East District, Vicenza, Italy
- Department of Oncology, University and General Hospital, Udine, Italy
| | - M Russano
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - S Cereda
- Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - F Leone
- Department of Oncology, University of Turin Medical School/Piedmont Foundation for Oncology, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy
| | - S Lonardi
- Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - L Fornaro
- Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126, Italy
| | - M Scartozzi
- Medical Oncology, Hospital & University of Cagliari, Italy
| | - N Silvestris
- Medical Oncology Unit, Cancer Institute ``Giovanni Paolo II'', 70124 Bari, Italy
| | - S Barni
- Medical Oncology Unit, ASST Bergamo Ovest, Piazzale Ospedale 1, 24047 Treviglio, Bergamo, Italy
| | - F Pantano
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - B Vincenzi
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| | - A Palloni
- Department of Experimental, Diagnostic and Speciality Medicine, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
| | - G Frega
- Department of Experimental, Diagnostic and Speciality Medicine, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
| | - M Casagrande
- Department of Oncology, University and General Hospital, Udine, Italy
| | - L Ferrari
- Department of Oncology, University and General Hospital, Udine, Italy
| | - V Dadduzio
- Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - R Intini
- Medical Oncology Unit 1, Department of Clinical and Experimental Oncology, Istituto Oncologico Veneto IOV-IRCCS, Padua, Italy
| | - R Filippi
- Department of Oncology, University of Turin Medical School/Piedmont Foundation for Oncology, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy
| | - E Vasile
- Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126, Italy
| | - C Vivaldi
- Unit of Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Via Roma 67, 56126, Italy
| | - L Faloppi
- Medical Oncology, Hospital of Macerata, Macerata, Italy & Medical Oncology, University of Cagliari, Italy
| | - O Brunetti
- Medical Oncology Unit, Cancer Institute ``Giovanni Paolo II'', 70124 Bari, Italy
| | - M Reni
- Department of Medical Oncology, San Raffaele Scientific Institute, Milan, Italy
| | - M Aglietta
- Department of Oncology, University of Turin Medical School/Piedmont Foundation for Oncology, Candiolo Cancer Institute - FPO, IRCCS, Candiolo, Italy
| | - G Tonini
- Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy
| |
Collapse
|
17
|
Fornaro L, Parnofiello A, Ugolini C, Cardarelli N, De Maglio G, Pecora I, Crivelli F, Catanese S, Cardellino G, Musettini G, Pella N, Pasquini G, Pizzolitto S, Salani F, Clerico M, Fontanini G, Fasola G, Maurizio D, Vivaldi C, Montagnani F. Predicting HER2 status in esophagogastric cancer: Development and validation of an easy-to-use nomogram. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
18
|
Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, Ryu MH, Fornaro L, Olesiński T, Caglevic C, Chung H, Muro K, Gökkurt E, Mansoor W, McDermott R, Schacham-Shmueli E, Chen X, Kang SP, Mayo C, Ohtsu A, Fuchs C. KEYNOTE-061: Phase 3 study of pembrolizumab vs paclitaxel for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy208.004] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Vivaldi C, Cappelli C, Donati F, Fornaro L, Musettini G, Pasquini G, Pecora I, Catanese S, Lencioni M, Salani F, Boraschi P, Falcone A, Vasile E. Analysis of early tumor shrinkage and depth of response in metastatic pancreatic cancer patients treated with first-line modified FOLFIRINOX or gemcitabine + nab-paclitaxel. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy151.158] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Franco P, Montagnani F, Arcadipane F, Casadei C, Andrikou K, Martini S, Iorio G, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Cascinu S, Ricardi U, Casadei Gardini A. EP-1461: Immune inflammation indicators in anal cancer patients treated with concurrent chemo-radiation. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31770-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
21
|
Martini S, Iorio G, Franco P, Montagnani F, Arcadipane F, Casadei C, Andrikou K, Scartozzi M, Mistrangelo M, Fornaro L, Cassoni P, Cascinu S, Ricardi U, Casadei Gardini A. EP-1487: The prognostic role of haemoglobin in patients undergoing concurrent chemo-radiation for anal cancer. Radiother Oncol 2018. [DOI: 10.1016/s0167-8140(18)31796-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
22
|
Casadei Gardini A, Passardi A, Fornaro L, Rosetti P, Valgiusti M, Ruscelli S, Monti M, Casadei C, Pagan F, Frassineti GL. Treatment of squamous cell carcinoma of the anal canal: A new strategies with anti-EGFR therapy and immunotherapy. Crit Rev Oncol Hematol 2018; 123:52-56. [PMID: 29482779 DOI: 10.1016/j.critrevonc.2018.01.007] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2017] [Revised: 11/22/2017] [Accepted: 01/16/2018] [Indexed: 12/24/2022] Open
Abstract
The incidence of squamous cell carcinoma of the anal canal (SCAC) is increasing in both sexes but the standard treatment remains that of 20 years ago. However, interesting data have recently emerged on the use of anti-epidermal growth factor receptor (EGFR) agents and immunotherapy in advanced disease. Thus, new avenues of research are opening up that will hopefully lead to more effective therapeutic strategies. We provide an overview of the latest studies published on this tumor and discuss the possible future therapeutic options for combination therapy, anti-EGFR treatment and radiotherapy.
Collapse
Affiliation(s)
- A Casadei Gardini
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Via Maroncelli, 40, 47014 Meldola, Italy.
| | - A Passardi
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Via Maroncelli, 40, 47014 Meldola, Italy
| | - L Fornaro
- Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa, Italy
| | - P Rosetti
- Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa, Italy
| | - M Valgiusti
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Via Maroncelli, 40, 47014 Meldola, Italy
| | - S Ruscelli
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Via Maroncelli, 40, 47014 Meldola, Italy
| | - M Monti
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Via Maroncelli, 40, 47014 Meldola, Italy
| | - C Casadei
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Via Maroncelli, 40, 47014 Meldola, Italy
| | - F Pagan
- Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Via P. Maroncelli, 40, 47014, Meldola, Italy
| | - G L Frassineti
- Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori (IRST) IRCCS, Via Maroncelli, 40, 47014 Meldola, Italy
| |
Collapse
|
23
|
Fornaro L, Vivaldi C, Lorenzoni G, Masi G, Bargellini I. Moving beyond sorafenib alone in advanced hepatocellular carcinoma: is hepatic arterial infusion chemotherapy the best option? Ann Oncol 2018; 28:667. [PMID: 27993799 DOI: 10.1093/annonc/mdw664] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Affiliation(s)
- L Fornaro
- Units of Medical Oncology 2; 2Radiology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa, Italy
| | - C Vivaldi
- Units of Medical Oncology 2; 2Radiology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa, Italy
| | - G Lorenzoni
- Units of Medical Oncology 2; 2Radiology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa, Italy
| | - G Masi
- Units of Medical Oncology 2; 2Radiology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa, Italy
| | - I Bargellini
- Units of Medical Oncology 2; 2Radiology, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa, Italy
| |
Collapse
|
24
|
Del Re M, Vivaldi C, Rofi E, Vasile E, Miccoli M, Caparello C, d'Arienzo P, Fornaro L, Falcone A, Danesi R. Early changes in plasma levels of mutant KRAS DNA as a sensitive marker of response to chemotherapy in pancreatic cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
25
|
Stasi I, Farnesi A, Vasile E, Petrini I, Luccchesi M, Lupi C, Sensi E, Giannini R, Fornaro L, Caparello C, Pasquini G, Puppo G, Finale C, Barletta M, Chella A, Allegrini G, Falcone A, Fontanini G. A retrospective analysis of patients (pts) with non-small-cell lung cancer (NSCLC) with uncommon or complex epidermal growth factor receptor (EGFR) mutations treated with tyrosine kinase inhibitors (EGFR-TKIs): clinical features and outcome. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
26
|
Morano F, Pietrantonio F, Barretta F, Fanotto V, Niger M, Nichetti F, Bergamo F, Silvestris N, Fornaro L, Bordonaro R, Baretti M, Santini D, Tomasello G, Antonuzzo L, Noventa S, Avallone A, Di Donato S, Maiello E, De Vita F, Aprile G. Estimation of 12-weeks life expectancy in patients (pts) with metastatic gastric cancer (mGC) candidated for second-line treatment: the “Gastric Life” nomogram. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
27
|
Vivaldi C, Arrigoni E, Morganti R, Pecora I, Fidilio L, Catanese S, Restante G, Fornaro L, Crucitta S, Lencioni M, Rofi E, Vasile E, Falcone A, Danesi R, Del Re M. Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
28
|
Fanotto V, Uccello M, Fornaro L, Rimassa L, Leone F, Rosati G, Santini D, Giampieri R, Di Donato S, Tomasello G, Silvestris N, Peverelli G, Battaglin F, Avallone A, Scartozzi M, Cinieri S, Melisi D, Antonuzzo L, Pellegrino A, Gerratana L, Aprile G. Second-line treatment efficacy in elderly vs. non-elderly advanced gastric cancer patients: an Italian multicentre real-world study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
29
|
Leone F, Filippi R, Palloni A, Fornaro L, Casadei Gardini A, Aprile G, Silvestris N, Satolli M, Faloppi L, Daniele S, Lutrino E, Vivaldi C, Frassineti G, Garattini S, Brunetti O, Russano M, Scartozzi M, Cagnazzo C, Aglietta M, Giovanni B. Prognostic factors in unresectable biliary tract cancer: a GICO (Gruppo Italiano COlangiocarcinoma) retrospective analysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.013] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
30
|
Pietrantonio F, Barretta F, Fanotto V, Niger M, Morano F, Bergamo F, Silvestris N, Fornaro L, Bordonaro R, Baretti M, Santini D, Tomasello G, Antonuzzo L, Noventa S, Avallone A, Di Donato S, Maiello E, De Vita F, Miceli R, Aprile G. Estimating 12-weeks life expectancy in metastatic gastric cancer (mGC) patients (pts) candidates for second-line treatment: The “Gastric Life” nomogram. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx369.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
31
|
Vivaldi C, Arrigoni E, Morganti R, Catanese S, Fidilio L, Pecora I, Restante G, Fornaro L, Crucitta S, Lencioni M, Rofi E, Vasile E, Falcone A, Danesi R, Del Re M. Analysis of DPYD and UGT1A1 genotype in patients with advanced pancreatic cancer treated with modified FOLFIRINOX. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx390.062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Pérez Barthaburu M, Galain I, Aguiar I, Bentos Pereira H, Bethencourt L, Miranda PB, Sampaio MF, Fornaro L. Hybridβ-HgS nanoparticles and P3HT layers for solar cells applications. ACTA ACUST UNITED AC 2017. [DOI: 10.1016/j.nanoso.2017.02.001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
33
|
Pietrantonio F, Caporale M, Morano F, Scartozzi M, Gloghini A, De Vita F, Giommoni E, Fornaro L, Aprile G, Melisi D, Berenato R, Mennitto A, Volpi CC, Laterza MM, Pusceddu V, Antonuzzo L, Vasile E, Ongaro E, Simionato F, de Braud F, Torri V, Di Bartolomeo M. HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research. Int J Cancer 2016; 139:2859-2864. [PMID: 27578417 DOI: 10.1002/ijc.30408] [Citation(s) in RCA: 64] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2016] [Revised: 07/18/2016] [Accepted: 08/17/2016] [Indexed: 12/21/2022]
Abstract
Mechanisms of acquired resistance to trastuzumab-based treatment in gastric cancer are largely unknown. In this study, we analyzed 22 pairs of tumor samples taken at baseline and post-progression in patients receiving chemotherapy and trastuzumab for advanced HER2-positive [immunohistochemistry (IHC) 3+ or 2+ with in-situ hybridization (ISH) amplification] gastric or gastroesophageal cancers. Strict clinical criteria for defining acquired trastuzumab resistance were adopted. Loss of HER2 positivity and loss of HER2 over-expression were defined as post-trastuzumab IHC score <3+ and absence of ISH amplification, and IHC "downscoring" from 2+/3+ to 0/1+, respectively. HER2 IHC was always performed, while ISH was missing in 3 post-progression samples. Patients with initial HER2 IHC score 3+ and 2+ were 14 (64%) and 8 (36%), respectively. Loss of HER2 positivity and HER2 over-expression was observed in 32 and 32% samples, respectively. The chance of HER2 loss was not associated with any of the baseline clinicopathological variables. The only exception was in patients with initial IHC score 2+ versus 3+, for both endpoints of HER2 positivity (80 vs. 14%; p = 0.008) and HER2 over-expression (63 vs. 14%; p = 0.025). As already shown in breast cancer, loss of HER2 may be observed also in gastric cancers patients treated with trastuzumab-based chemotherapy in the clinical practice. This phenomenon may be one of the biological reasons explaining the failure of anti-HER2 second-line strategies in initially HER2-positive disease.
Collapse
Affiliation(s)
- F Pietrantonio
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
| | - M Caporale
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - F Morano
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M Scartozzi
- Medical Oncology Department, Azienda Ospedaliera Universitaria Cagliari, Presidio Policlinico Universitario "Duilio Casula", Cagliari, Italy
| | - A Gloghini
- Diagnostic pathology and laboratory medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - F De Vita
- Medical Oncology Department, Seconda Università degli studi di Napoli, Naples, Italy
| | - E Giommoni
- Medical Oncology 1, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
| | - L Fornaro
- U.O. Oncologia Medica 2 Universitaria, Ospedale S. Chiara - Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano, Tumori, Italy
| | - G Aprile
- Medical Oncology Department, University and General Hospital, Udine, Italy
| | - D Melisi
- Medical Oncology, Università degli studi di Verona, Italy
| | - R Berenato
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - A Mennitto
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - C C Volpi
- Diagnostic pathology and laboratory medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M M Laterza
- Medical Oncology Department, Seconda Università degli studi di Napoli, Naples, Italy
| | - V Pusceddu
- Medical Oncology Department, Azienda Ospedaliera Universitaria Cagliari, Presidio Policlinico Universitario "Duilio Casula", Cagliari, Italy
| | - L Antonuzzo
- Medical Oncology 1, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
| | - E Vasile
- U.O. Oncologia Medica 2 Universitaria, Ospedale S. Chiara - Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano, Tumori, Italy
| | - E Ongaro
- Medical Oncology Department, University and General Hospital, Udine, Italy
| | - F Simionato
- Medical Oncology, Università degli studi di Verona, Italy
| | - F de Braud
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.,Oncology Department, University of Milan, Italy
| | - V Torri
- Oncology Department, IRCCS-Mario Negri Institute for Pharmacological Rresearch, Milan, Italy
| | - M Di Bartolomeo
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
34
|
Vivaldi C, Buccianti P, Musettini G, Bergamo F, Rizzato M, Sainato A, Martignetti A, Lucchesi S, Franceschi M, Boso C, Pasqualetti F, Ginocchi L, Di Clemente F, Gonnelli A, Urbani L, Fornaro L, Montrone S, Maretto I, Balestro R, Falcone A, Masi G. TRUST: phase II trial of induction chemotherapy (CT) with FOLFOXIRI plus bevacizumab (BV) followed by chemo-radiotherapy (CRT) plus BV and surgery in locally advanced rectal carcinoma (LARC). Ann Oncol 2016. [DOI: 10.1093/annonc/mdw335.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
35
|
Montagnani F, Fornaro L, Frumento P, Falcone A, Fioretto L. Mixed meta-analysis of treatment options for locally advanced oesophageal squamous-cell carcinoma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw333.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
36
|
Aprile G, Fanotto V, Vivaldi C, Fontanella C, Bordonaro R, Leone F, Rimassa L, Rosati G, Pasquini G, Tomasello G, Ferrari L, Santini D, Giampieri R, Pietrantonio F, Cordio S, Filippi R, Bozzarelli S, Caparello C, Fornaro L. Characteristics and outcomes of advanced gastric cancer patients treated with at least three lines of chemotherapy: analysis on 300 Italian real-world cases. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw333.08] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Vivaldi C, Vasile E, Caparello C, Perrone V, Caniglia F, De Lio N, Croce C, Fornaro L, Musettini G, Pasquini G, Pecora I, Lencioni M, Cappelli C, Caramella D, Falcone A, Boggi U. PD-022 FOLFOXIRI as primary treatment for locally advanced unresectable pancreatic cancer (LAPC): a prospective study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw200.22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Musettini G, Caparello C, Vivaldi C, Pasquini G, Lencioni M, Petrini I, Fornaro L, Vasile E, Falcone A. Palliative gastrectomy in asymptomatic metastatic esophagogastric cancer (EGC): does it make sense? Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.29] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
39
|
Caparello C, Vasile E, Fornaro L, Lencioni M, Petrini I, Vivaldi C, Pasquini G, Musettini G, Falcone A. Tolerability of FOLFOXIRI regimen after surgical resection for pancreatic cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.48] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
Vasile E, Vivaldi C, Fornaro L, Caparello C, Musettini G, Pasquini G, Catanese S, Lencioni M, Ricci S, Falcone A. Second-line chemotherapy after disease progression following first-line FOLFOXIRI in advanced pancreatic cancer patients. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.26] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
41
|
Brandi G, Cereda S, Pantano F, Russano M, Lonardi S, Leone F, Reni M, Marsico V, Filippi R, Delcuratolo S, Fornaro L, Vasile E, Vivaldi C, Aprile G, Pisconti S, Luca F, Aieta M, Tonini G, Santini D. Natural history of skeletal disease in primary biliary cancers. National survey on behalf of GICO group (Gruppo Italiano Colangiocarcinoma – Onlus). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
42
|
Fornaro L, Cereda S, Leone F, Aprile G, Lonardi S, Silvestris N, Santini D, Milella M, Palloni A, Barbera A, Ferrari L, Filippi R, Bergamo F, Vivaldi C, Caparello C, Musettini G, Pasquini G, Falcone A, Reni M, Brandi G, Vasile E. Second-line chemotherapy (CT2) in advanced biliary tract cancer (aBTC) patients (pts) progressed to first-line chemotherapy (CT1) with gemcitabine plus platinum: where are we now? Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Vivaldi C, Vasile E, Fornaro L, Pasquini G, Catanese S, Caparello C, Musettini G, Lencioni M, Ricci S, Falcone A. Prognostic model for patients (pts) with advanced pancreatic cancer (aPC) receiving first-line modified FOLFIRINOX (mFOLFIRINOX). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv344.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
44
|
Vivaldi C, Vasile E, Fornaro L, Caparello C, Musettini G, Pasquini G, Lencioni M, Ricci S, Falcone A. 2362 Second-line treatment after disease progression following first-line chemotherapy with modified FOLFIRINOX in advanced pancreatic cancer patients. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31278-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
45
|
Fornaro L, Vivaldi C, Brandi G, Cereda S, Aprile G, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Caparello C, Musettini G, Pasquini G, Vasile E. P-147 Outcome of second-line chemotherapy (CT2) after first-line CT (CT1) with platinum plus gemcitabine in advanced biliary tract cancer (aBTC): is it worthwhile? Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.147] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
46
|
Marsico V, Vasile E, Brandi G, Leone F, Santini D, Aprile G, Cereda S, Silvestris N, Milella M, Bergamo F, Fornaro L, Bolshinsky M, Paladina I, Lonardi S, Aliberti C. P-115 Transarterial Chemo-Embolization (TACE) and Radio-Embolization (TARE) in the combined modality treatment of advanced biliary tract cancer (aBTC): evaluation of feasibility and activity. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv233.115] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
47
|
Masi G, Salvatore L, Boni L, Loupakis F, Cremolini C, Fornaro L, Schirripa M, Cupini S, Barbara C, Safina V, Granetto C, Fea E, Antonuzzo L, Boni C, Allegrini G, Chiara S, Amoroso D, Bonetti A, Falcone A. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol 2015; 26:724-730. [PMID: 25600568 DOI: 10.1093/annonc/mdv012] [Citation(s) in RCA: 116] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND The combination of bevacizumab with fluorouracil-based chemotherapy is a standard first-line treatment option in metastatic colorectal cancer (mCRC). We studied the efficacy of continuing or reintroducing bevacizumab in combination with second-line chemotherapy after progression to bevacizumab-based first-line therapy. PATIENTS AND METHODS In this phase III study, patients with mCRC treated with fluoropyrimidine-based first-line chemotherapy plus bevacizumab were randomized to receive in second-line mFOLFOX-6 or FOLFIRI (depending on first-line regimen) with or without bevacizumab. The primary end point was progression-free survival. To detect a hazard ratio (HR) for progression of 0.70 with an α and β error of 0.05 and 0.20, respectively, 262 patients were required. RESULTS In consideration of the results of the ML18147 trial, the study was prematurely stopped. Between April 2008 and May 2012, a total of 185 patients were randomized. Bevacizumab-free interval was longer than 3 months in 43% of patients in chemotherapy alone arm and in 50% of patients in the bevacizumab arm. At a median follow-up of 45.3 months, the median progression-free survival was 5.0 months in the chemotherapy group and 6.8 months in the bevacizumab group [adjusted HR = 0.70; 95% confidence interval (CI) 0.52-0.95; stratified log-rank P = 0.010]. Subgroup analyses showed a consistent benefit in all subgroups analyzed and in particular in patients who had continued or reintroduced bevacizumab. An improved overall survival was also observed in the bevacizumab arm (adjusted HR = 0.77; 95% CI 0.56-1.06; stratified log-rank P = 0.043). Responses (RECIST 1.0) were similar in the chemotherapy and bevacizumab groups (17% and 21%; P = 0.573). Toxicity profile was consistent with previously reported data. CONCLUSIONS This study demonstrates that the continuation or the reintroduction of bevacizumab with second-line chemotherapy beyond first progression improves the outcome and supports the use of this strategy in the treatment of mCRC. ClinicalTrials.gov number: NCT00720512.
Collapse
Affiliation(s)
- G Masi
- Division of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa.
| | - L Salvatore
- Division of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa
| | - L Boni
- Clinical Trials Coordinating Center, AOU Careggi/Istituto Toscano Tumori, Firenze
| | - F Loupakis
- Division of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa
| | - C Cremolini
- Division of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa
| | - L Fornaro
- Division of Medical Oncology, Azienda USL 2 di Lucca, Istituto Toscano Tumori, Lucca
| | - M Schirripa
- Division of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa
| | - S Cupini
- Division of Medical Oncology, Azienda USL 6 di Livorno, Istituto Toscano Tumori, Livorno
| | - C Barbara
- Division of Medical Oncology, Azienda USL 6 di Livorno, Istituto Toscano Tumori, Livorno
| | - V Safina
- Division of Medical Oncology, Azienda USL 6 di Livorno, Presidio Ospedaliero di Piombino, Istituto Toscano Tumori, Piombino
| | - C Granetto
- Division of Medical Oncology, Ospedale S. Croce e Carle, Cuneo
| | - E Fea
- Division of Medical Oncology, Ospedale S. Croce e Carle, Cuneo
| | - L Antonuzzo
- Division of Medical Oncology 1, Azienda Ospedaliero-Universitaria Careggi, Istituto Toscano Tumori, Firenze
| | - C Boni
- Division of Medical Oncology, Arcispedale Santa Maria Nuova-IRCCS, Reggio Emilia
| | - G Allegrini
- Division of Medical Oncology, Azienda USL 5 di Pisa, Ospedale Felice Lotti, Istituto Toscano Tumori, Pontedera
| | - S Chiara
- Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria San Martino-Istituto Nazionale Ricerca Cancro, Genova
| | - D Amoroso
- Division of Medical Oncology, Ospedale della Versilia, Istituto Toscano Tumori, Lido di Camaiore
| | - A Bonetti
- Division of Medical Oncology, AULSS 21 Legnago, Ospedale Mater Salutis, Legnago, Italy
| | - A Falcone
- Division of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa
| | | |
Collapse
|
48
|
Vivaldi C, Fornaro L, Cereda S, Aprile G, Santini D, Silvestris N, Lonardi S, Leone F, Milella M, Brandi G, Vasile E. Second-line chemotherapy in advanced biliary cancer: the present now will later be past. Ann Oncol 2014; 25:2443-2444. [PMID: 25122694 DOI: 10.1093/annonc/mdu379] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- C Vivaldi
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa
| | - L Fornaro
- Unit of Medical Oncology, Azienda USL2 Lucca, Lucca
| | - S Cereda
- Department of Medical Oncology, San Raffaele Scientific Institute, Milan
| | - G Aprile
- Department of Oncology, University and General Hospital, Udine
| | - D Santini
- Department of Medical Oncology, University Campus Bio-Medico, Rome
| | - N Silvestris
- Unit of Medical Oncology, National Cancer Institute Giovanni Paolo II, Bari
| | - S Lonardi
- Unit of Medical Oncology 1, Istituto Oncologico Veneto, IRCCS, Padova
| | - F Leone
- Unit of Medical Oncology, Institute for Cancer Research and Treatment IRCCS Candiolo, University of Torino, Turin
| | - M Milella
- Medical Oncology A, Regina Elena National Cancer Institute, Rome
| | - G Brandi
- Unit of Medical Oncology, Sant'Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
| | - E Vasile
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, University of Pisa, Pisa;.
| |
Collapse
|
49
|
Carrieri L, Sgaramella T, Bortolon F, Stenta G, Fornaro L, Cracco A, Perini F, Soresi S. Determinants of on-the-job-barriers in employed persons with multiple sclerosis: The role of disability severity and cognitive indices. Work 2014; 47:509-20. [DOI: 10.3233/wor-131623] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Affiliation(s)
- L. Carrieri
- Dipartimento di Scienze Filosofiche, Università di Cassino, Cassino, Italy
| | - T.M. Sgaramella
- Dipartimento di Psicologia dello Sviluppo e della Socializzazione, Università di Padova, Padova, Italy
| | - F. Bortolon
- Divisione di Neurologia, Ospedale Civile S. Bortolo, Vicenza, Italy
| | - G. Stenta
- Divisione di Neurologia, Ospedale Civile S. Bortolo, Vicenza, Italy
| | - L. Fornaro
- Centro Sclerosi Multipla e Continuità Assistenziale Neurologica, Ospedale S. Bortolo, Vicenza, Italy
| | - A. Cracco
- Servizio di Psicologia, Ospedale Civile S. Bortolo, Vicenza, Italy
| | - F. Perini
- Divisione di Neurologia, Ospedale Civile S. Bortolo, Vicenza, Italy
| | - S. Soresi
- Dipartimento di Psicologia dello Sviluppo e della Socializzazione, Università di Padova, Padova, Italy
| |
Collapse
|
50
|
Fornaro L, Lonardi S, Masi G, Loupakis F, Bergamo F, Salvatore L, Cremolini C, Schirripa M, Vivaldi C, Aprile G, Zaniboni A, Bracarda S, Fontanini G, Sensi E, Lupi C, Morvillo M, Zagonel V, Falcone A. FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 2013; 24:2062-7. [PMID: 23666916 DOI: 10.1093/annonc/mdt165] [Citation(s) in RCA: 80] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND The FOLFOXIRI regimen developed by the Gruppo Oncologico Nord Ovest (GONO) demonstrated higher activity and efficacy compared with FOLFIRI in metastatic colorectal cancer (mCRC). Panitumumab is effective in some patients with KRAS codon 12-13 wild-type mCRC. KRAS codon 61, HRAS, NRAS, and BRAF V600E mutations might predict resistance to anti-epidermal growth factor receptor antibodies. PATIENTS AND METHODS We conducted a phase II study evaluating the combination of panitumumab (6 mg/kg on day 1) with a slightly modified GONO-FOLFOXIRI (irinotecan 150 mg/m², oxaliplatin 85 mg/m², and folinate 200 mg/m² on day 1, followed by fluorouracil 3000 mg/m² as a 48-h continuous infusion starting on day 1) repeated every 2 weeks as first-line treatment of wild-type KRAS, HRAS, NRAS (codon 12-13-61), and BRAF unresectable mCRC patients. Fluorouracil dose was reduced to 2400 mg/m² after two of the first three patients reported grade 3-4 diarrhoea (in one case with febrile neutropenia). Induction treatment was scheduled for a maximum of 12 cycles, followed by panitumumab ± fluorouracil/folinate maintenance until progression. Primary end point was overall response rate (ORR). RESULTS Eighty-seven patients were screened and 37 were enrolled. Thirty-three patients achieved an objective response (ORR: 89%; 95% CI 75% to 96%). Sixteen patients (43%) underwent secondary surgery of metastases, and R0 resection was achieved in 13 cases (35%). At a median follow-up of 17.7 months, median progression-free survival was 11.3 months (95% CI 9.7-12.9 months). After amendment, most common grade 3-4 adverse events reported during induction treatment were neutropenia (48%; febrile neutropenia: 5%), diarrhoea (35%), asthenia (27%), stomatitis (14%), and skin toxic effect (14%). One treatment-related death was registered. CONCLUSIONS Adding panitumumab to FOLFOXIRI is feasible decreasing the dose of fluorouracil and irinotecan to reduce the risk of diarrhoea. Activity and secondary resectability of metastases among Ras-BRAF wild-type patients are promising.
Collapse
Affiliation(s)
- L Fornaro
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|